Problematically, however, the later IMpower110 NSCLC frontline atezolizumab trial compared IHC SP142 to IHC 22C3 in pre-specified exploratory analyses and showed the SP142 assay was less sensitive for staining both tumor and immune cell PD-L1 [29]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.